Ratings Pacific Biosciences of California, Inc. BOERSE MUENCHEN

Equities

P09

US69404D1081

Real-time BOERSE MUENCHEN Other stock markets 13:13:35 03/07/2024 BST			5-day change	1st Jan Change
1.196 ^EUR	+1.56%		-9.97%	-87.43%

07-01	Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index	CI
06-27	PacBio, Form Bio Team Up to Launch Initiatives to Unify AAV Gene Therapy Industry	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company appears to be poorly valued given its net asset value.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's enterprise value to sales, at 4.35 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-87.43%	349M	-
THERMO FISHER SCIENTIFIC	+0.59%	204B	B
DANAHER CORPORATION	+3.92%	178B	B-
INTUITIVE SURGICAL, INC.	+30.07%	156B	B-
BOSTON SCIENTIFIC CORPORATION	+32.42%	113B	A-
SIEMENS HEALTHINEERS AG	+1.98%	64.26B	A-
EDWARDS LIFESCIENCES CORPORATION	+19.65%	54.98B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.86%	47.44B	B+
AGILENT TECHNOLOGIES, INC.	-9.53%	36.7B	A
GE HEALTHCARE TECHNOLOGIES INC.	-1.28%	34.84B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes